Endocrine Flashcards
Drug class for Levothyroxine
thyroid agent (T4)
MoA for Levothyroxine
replacement T4 converted to T3 in peripheral tissues -> nuclear receptors -> protein synthesis, metabolic rate, promotes gluconeogenesis
Indications for Levothyroxine
hypothyroidism, thyroid cancer
Drug class for Liothyronine
thyroid agent (T3)
MoA for Liothyronine
T3 in peripheral tissues -> nuclear receptors -> protein synthesis, metabolic rate, promotes gluconeogenesis
Indications for Liothyronine
hypothyroidism not responsive to T4 therapy; tx of myxedema coma
Drug class for Radioactive Iodine
antithyroid agent
MoA for Radioactive Iodine
radioactive iodine is concentrated in thyroid gland w/ death of gland cells over 6-8 weeks
Indications for Radioactive Iodine
thyroid ablation without surgery
Drug class for Methimazole
antithyroid agents
MoA for Methimazole
blocks oxidation of iodine in thyroid gland preventing iodine combining w/ tyroisin to form T4, T3; doesn’t inactivate circulating T4, T3
Indications for Methimazole
hyperthyroidism
Drug class for Prophylthiouracil [PTU]
anti-thyroid drug
thiamine
MoA for Prophylthiouracil [PTU]
interfere w/ thyroid hormone synthesis; inhibits conversion of T4 to T3; has immunosuppressive effects (bone marrow)
Indications for Prophylthiouracil [PTU]
Graves disease, pre-thyroid surgery or RAI131 therapy, thyrotoxic crisis
Drug class for Prednisone
glucocorticoids
Drug class for Prednisolone
glucocorticoids intermediate acting
Drug class for Dexamethasone
glucocorticoids long acting
MoA for Prednisone, Prednisolone, Dexamethasone
suppresses adrenal function at high dose; dec leukocyte migration; enters cell nucleus to alter synthesis of protein
Indications for Prednisone, Prednisolone, Dexamethasone
multiple; immunosuppressive functions
Drug class for Fludrocortisone
mineralcorticoids
MoA for Fludrocortisone
promotes increased distal renal tubule absorption of Na+ and loss of K+
Indications for Fludrocortisone
Addison’s disease (adrenocortical insufficiency); resistant orthostatic hypotension
Drug class for Propanolol
adjunct drugs: nonselective beta blocker
MoA for Propanolol
adrenergic B1 & B2 receptor inhibitor; reduction in myocardial oxygen demand
Indications for Propanolol
angina, HTN, tachycarrhythmias, essential tremor, migraine Pa, anxiety
Drug class for Metoprolol
adjunct drugs: selective beta blockers (B1)
MoA for Metoprolol
selective B1 adrenergic receptor inhibitor
Indications for Metoprolol
angina, HTN, hemodynamically stable MI
Drug class for Raloxifine
selective estrogen receptor modulators (SERMs)
MoA for Raloxifine
binds to selected estrogen receptors & dec bone resorption
Indications for Raloxifine
px/tx osteoporosis
Drug class for Alendronate
bisphosphenate: oral
MoA for Alendronate
decrease rate of bone resorption
Indications for Alendronate
px/tx of osteoporosis in women; tx in men; Paget’s disease
Drug class for Zoledronic Acid
bisphosphenate: IV
MoA for Zoledronic Acid
inhibits osteoclast activity & skeletal calcium release
Indications for Zoledronic Acid
px/tx osteoporosis; tx multiple myeloma, metastatic bone lesions, hypercalcemia of malignancy, Paget’s disease
Drug class for Calcitonin Salmon
calcitonin
MoA for Calcitonin Salmon
protein sequence similar to human calcitonin; antagonizes impact of parathyroid hormone & inhibits osteoclast activity
Indications for Calcitonin Salmon
osteoporosis, Paget’s disease, hypercalcemia
Drug class for Teriparatide
recombinant human parathyroid hormone
MoA for Teriparatide
recombinant form PTH (1-34); stimulates new bone formation
Indications for Teriparatide
tx severe/tx-resistant osteoporosis (max 2 yrs use)
Drug class for Denosumab
RANK ligand inhibitor
MoA for Denosumab
human monoclonal antibody which attaches to RANKL blocking ability to bind to RANK receptor on surface of osteoclast thereby inhibiting osteoclastogenesis & increasing osteoclast apoptosis
Indications for Denosumab
males & postmenopausal females at high fracture risk due to osteoporosis; men on androgen-deprivation therapy & women receiving aromatase-inhibitor therapy
Drug class for Glipizide
sulfonylureas
MoA for Glipizide
stimulates pancreatic beta cell release of insulin (closes KATP channels -> (+) insulin)
Indications for Glipizide
T2DM
Drug class for Repaglinide
Meglitinides
MoA for Repaglinide
binds to adjacent receptor to sulfonylurea receptor on beta cell to stimulate insulin release
Indications for Repaglinide
T2DM; reduction of postprandial glucose levels; sulfa allergy
Drug class for Metformin
biguanides
MoA for Metformin
decrease hepatic glucose production, decrease renal gluconeogenesis, slow intestinal absorption glucose, increase glucose conversion to lactate by enterocytes, stimulate tissue glycolysis, increase glucose removal from blood, decrease plasma glucagon levels
Indications for Metformin
T2DM
Drug class for Pioglitizone
TZDs
MoA for Pioglitizone
decrease insulin resistance by activation of nuclear PPAR-gamma in myocytes, hepatocytes; most potent insulin sensitizer, increase trig metabolism (site: muscle, fat, liver cells)
Indications for Pioglitizone
T2DM
Drug class for Acarbose
alpha-glucosidase inhibitor
MoA for Acarbose
reduces postprandial glucose levels by inhibition of intestinal alpha-glucosidase conversion polysaccharides to monosaccharides; delays absorption & levels of blood glucose
Indications for Acarbose
T1DM, T2DM
Drug class for Sitagliptin
dipeptidul peptidase-4 inhibitor
MoA for Sitagliptin
inhibits DPP-4 to reduce degradation of GLP-1 -> increases levels of CLP-1; reduces postprandial glucose levels
Indications for Sitagliptin
T2DM
Drug class for Lispro
rapid acting insulin
MoA for Lispro
insulin replacement, supplement
Indications for Lispro
T1DM, T2DM
Drug class for Regular
short acting insulin
MoA for Regular
insulin replacement, supplement
Indications for Regular
T1DM, T2DM
Drug class for Neutral Protamine
intermediate acting insulin
MoA for Neutral Protamine
insulin replacement, supplement
Indications for Neutral Protamine
T1DM, T2DM
Drug class for Insulin Glargine
long acting insulin
MoA for Insulin Glargine
insulin replacement, supplement
Indications for Insulin Glargine
T1DM, T2DM
Drug class for Human rDNA Insulin
oral inhalation, rapid acting insulin
MoA for Human rDNA Insulin
inhaled insulin
Indications for Human rDNA Insulin
T1DM, T2DM used w/ long acting insulin
Drug class for Pramlintide
amylin analogue
MoA for Pramlintide
amylin analogue (decrease gastric emptying, decrease glucagon secretion, decrease appetite)
Indications for Pramlintide
T1DM, T2Dm to lower PP glucose levels
Drug class for Exenatide
incretin mimetic: GLP-1 agonist
MoA for Exenatide
increase insulin release; decrease glucagon release; slows gastric emptying; decrease appetite; stimulates insulin secretion in presence of glucose
Indications for Exenatide
T2DM w/ metformin +/- sulfonylurea to lower PP glucose levels
Drug class for Liraglutide
incretin mimetic: GLP-1 agonist
MoA for Liraglutide
increase insulin release; decrease glucagon release; slows gastric emptying; decrease appetite; increase beta cell growth/replication
Indications for Liraglutide
T2DM w/ metformin +/- sulfonylurea to lower PP glucose levels
Drug class for Canaglifloxin
SGLT2 inhibitor
MoA for Canaglifloxin
inhibits glucose resorption in proximal renal tubule
Indications for Canaglifloxin
adjunct therapy in T2DM
Drug class for Colesevelam
bile acid sequestrant
MoA for Colesevelam
decrease intestinal glucose absorption
Indications for Colesevelam
hypercholesterolemia, adjunct to metformin, sulfonylureas, insulin in T2DM
Drug class for Desmopressin
vasopressin receptor agonist
MoA for Desmopressin
increase permeability of renal tubular cells to water resorption -> decrease urine volume, increase vonW factor, VIII, t-PA levels
What does parathyroid hormone stimulate?
stimulates bone resorption
What are the main cells in the ileum & what do they release?
L cells release glucagon-like peptide-1 (GLP-1)
What are the main cells in the jejunum & what do they release?
K cells release glucose-dependent insulinotropic polypeptide (GIP)
What to acing cells secrete?
digestive enzymes
What are the two types of cells in the Islets of Langerhans?
alpha & beta cells
What to alpha cells do?
secrete glucagon -> hepatic glycogenolysis -> glucose between meals
What do beta cells do?
secrete insulin -> glucose entry into cells
secrete amylin -> inhibits gastric emptying, glucagon release
What do delta cells do?
secrete somatostatin -> acts locally to decrease beta cell release of insulin, amylin production
What are the functions of insulin?
- promote glucose uptake by tissue cells
- promotes protein synthesis
- provides for glucose storage
- prevents fat & glycogen breakdown
- inhibits gluconeogenesis
Which drugs increase insulin secretion in T2DM?
sulfonylureas, meglitinides, uncertain mimetic, gut-derived hormone analogues, DPP-4 inhibitors
Which drugs decrease insulin resistance in T2DM?
biguanides, TZDs
Which drugs decrease hepatic gluconeogenesis in T2DM?
biguanides, amylin analogue
Which drugs decrease glucose absorption in T1DM & T2DM?
alpha-glucosidase inhibitors, bile acid sequestrants